All In Biotech

Drug Trial Radar · NCT04952064

An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke

Ganglioside GM1 in Acute Ischemic Stroke: a Prospective, Randomized, Blinded Assessment of Endpoints, and Multicenter Exploratory Study

Last checked: Nov 19, 2026Latest source record: Sep 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jul 28, 2021

Primary completion

Jul 18, 2022

Study completion Jul 18, 2022

Sponsor

Lead sponsor
General Hospital of Shenyang Military RegionAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Third Xiangya Hospital of Central South University
First posted
Jul 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.

Conditions

  • Stroke, Ischemic

Interventions

  • Monosialoganglioside GM1Drug

    Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of modified Rankin Scale (mRS) 0-2Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Hospital of ShenYang Military Region

    Shenyang, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.